Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Celularity Inc (CELU)

Celularity Inc (CELU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Celularity Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors PR Newswire - Wed Jul 19, 2023

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

CELU : 3.14 (+5.02%)
CELULARITY ANNOUNCES $45 MILLION PURCHASE ORDER, FIRST MIDDLE EAST PRIVATE LABEL AGREEMENT FOR CELULARITY'S HALAL-CERTIFIED BIOMATERIAL PRODUCTS PR Newswire - Tue May 23, 2023

/PRNewswire/ -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial...

CELU : 3.14 (+5.02%)
Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the GCC and Egypt PR Newswire - Tue Mar 28, 2023

/PRNewswire/ -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a biotechnology company developing placental-derived allogenic cell therapies and biomaterial...

CELU : 3.14 (+5.02%)
Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East PR Newswire - Wed Jan 11, 2023

/PRNewswire/ -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and...

CELU : 3.14 (+5.02%)
Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia PR Newswire - Wed Jan 11, 2023

/PRNewswire/ -- Celularity Inc. (NASDAQ: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and...

CELU : 3.14 (+5.02%)
Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia Business Wire - Wed Jan 11, 2023

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC (“CH Trading...

CELU : 3.14 (+5.02%)
Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East Business Wire - Wed Jan 11, 2023

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC (“CH Trading...

CELU : 3.14 (+5.02%)
Celularity Announces Halal Certification of its Advanced Cellular Therapeutics, Biomaterial Products and Business Model Business Wire - Mon Dec 5, 2022

Celularity Inc. (Nasdaq: CELU) (“Celularity” or “the “Company”), a clinical-stage biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, today announced...

CELU : 3.14 (+5.02%)
Celularity CEO Robert J. Hariri, M.D., Ph.D., Addresses FII Conference on “The Science and Technology for Extending Healthy Human Lifespan” Business Wire - Wed Nov 30, 2022

Celularity, Inc. (Nasdaq: CELU) (“Celularity” or “the Company”), a clinical-stage biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, shared today...

CELU : 3.14 (+5.02%)
Celularity Reports Second Quarter 2022 Financial Results and Corporate Update Globe Newswire - Tue Aug 9, 2022

- Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction...

CELU : 3.14 (+5.02%)

Barchart Exclusives

Tesla Stock Forecast Post-Q2 Earnings: 'Present Imperfect, Future Uncertain' Barchart - 16 minutes ago
Tesla stock crashed following its Q2 earnings earlier this week. Here are the key takeaways from the report, and the forecast for the company amid a challenging macro environment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot